Jak citovat
Abstrakt
When Severe Acute Respiratory human Coronavirus 2 (SARS-hCOV 2) infection began in December 2019, detailed knowledge about the virus was lacking. This included non-availability of anti-viral treatment or vaccine, no knowledge of virus-human interaction, and lack of prognostic factors for stages of illness among others. A publication in Nigerian Journal of Physiological Sciences (2020). 35: 20-25 titled “Immune Responses During Human Coronavirus Infection: Suggestions For Future Studies” adduced investigations into immune parameters of COVID-19 patients so as to throw more light on the immunopathogenesis of SAR-CoV-2 infection, in order to create avenue for the development of vaccines or herd immunity. This present publication is a review of studies carried out on COVID-19 patients in one Infectious Diseases Center (I.D.C), Ibadan, Nigeria as a response to the gaps in knowledge raised in above mentioned publication. Cummulatively, immune-metabolic studies from this IDC revealed mild, age- and sex-dependent status of COVID-19 in patients admitted into this center. Thus, explaining the basis for the effectiveness of adopted re-purposed drugs (chloroquine or hydroxychloroquine, zinc, vitamins C and D and or antibiotics), physiotherapy and nutritional support used for the management of admitted COVID-19 patients. Also, this paper vindicated that inflammation was heightened during SARS-CoV 2 infection; therefore therapeutic interventions to control the inflammatory processes, oxidative stress, antibodies against structural and non-structural proteins or blocks receptor sites were proposed. In addition, development of herd immunity and efficacy of COVID-19 vaccines (Astrazeneca and Moderna) were elucidated in general population. However, study to determine host genetic factors in hCoV infection was lacking. This review concluded that interdisciplinary collaborative approach will be useful in the management of future emerging or re-emerging infection
Reference
Akinwumi JA, Edem VF, Arinola GO. (2021). Cellular inflammatory indices in hospitalised Nigerian COVID-19 patients. Journal Health Science Research. 6(2): 19-26.
Akinwumi J, Edem VF, Arinola, OG. (2023). Calculated Nutritional Indices in Symptomatic Hospitalized Nigerian COVID-19 Patients. Nigerian Journal of Physiological Sciences, 38(1), 17–22. https://doi.org/10.54548/njps.v38i1.4.
Alonge O and Arinola G. (2022). Haematological Changes and Metabolic Alterations in SARS-CoV-2 Infected Patients Hospitalised At an Infectious Diseases Center, Ibadan, Nigeria. Eur.J. Clin. And Exp. Med. 20(4): 383-390.
Alonge O, Fowotade A, Bamidele F, Omotosho T, Aboluwoye, M, Olulana S, Fashina N, Famuyiwa F, Eegunjobi A, Arinola G. (2022). Clinical Outcome Of Corona Virus Disease-19 Patients In An Infectious Disease Center, Olodo, Ibadan, Oyo State, Nigeria. Clinical Medicine Insights, 32; 287–296.
Ankerhold J, Giese S, Kolb P, Maul-Pavicic A, Voll RE, Göppert N, Ciminski K, Kreutz C, Lother A, Salzer U, Bildl W, Welsink T, Morgenthaler NG, Grawitz AB, Emmerich F, Steinmann D, Huzly D, Schwemmle M, Hengel H, Falcone V. (2022). Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nat Commun. Sep 26;13(1):5654. doi: 10.1038/s41467-022-32867-z. PMID: 36163132; PMCID: PMC9513013.
Anyanwu MU. (2021). The association between malaria prevalence and COVID-19 mortality. BMC Infect Dis. Sep 19;21(1):975. doi: 10.1186/s12879-021-06701-8. PMID: 34538242; PMCID: PMC8449890.
Arinola G.O, Alonge T.O, Edem F.V, Fowotade A, Fashina O.A, Akinbola O.I, Akinbile S.A, Eegunjobi A.O, Bello M.D, Fagbemi O.S, Salami F, Johnson J.O, Oke A.C, Famuyiwa O.I, Olaoti A.J, Olaniyan O.A, Ishola C.O. (2021e). Changes in Selected Renal Function Parameters of Newly Admitted COVID-19 Patients from One Infectious Diseases Center in Ibadan, Nigeria: Indication for Immunopathology. Nig. J. Physiol. Sci. 36: 11 – 15.
Arinola GO, Onifade AA, Edem VF, Rahamon SK, Alonge OT. (2023a). Immunometabolic Profile of Nigerian COVID-19 Patients. Journal of Health Science and Medical Research, [S.l.], p. e2023945, mar. 2023. ISSN 2630-0559. Available at: <https://www.jhsmr.org/index.php/jhsmr/article/view/945>.
Arinola GO, Edem FV, Fashina OA, Olaniyan OA, Alonge TO. (2021b). Cellular and Humoral Factors of Oxidative Burst in COVID-19 Patients with Malaria Parasiteamia. Annals of Epidemiology & Public Health. 4(1): 1060-1065.
Arinola GO, Edem VF, Alonge TO. (2021a). Respiratory Burst Functions in COVID-19 Nigerian Patients. Journal of Basic and Applied Research in Biomedicine. 7(1): 24-28.
Arinola GO, O.A. Fashina, O.C. Oluyomi Ishola, O.I. Akinbola, S.A. Akinbile, A.O. Eegunjobi, M.D. Bello, F.V. Edem, S.K. Rahamon, O.I. Famuyiwa, A.J. Olaoti, O.A.Olaniyan, A.C. Oke, A. Fowotade, O. Abimbola, J.O. Johnson, O.S. Fagbemi, Funmi Salami, T.O. Alonge (2021c). Demographic attributes of COVID-19 patients in an infectious disease center of Nigeria. Afr. Journal of Clinical and Experimental Microbiology. 22(1): 21-27.
Arinola GO, Onifade AA, Adigun K, Oshingbesan MB. (2023a). Serum levels of IFN-γ and IL-4 in hospitalised COVID-19 patients – evidence of reduced cytokine storm in discharged patients. Eur J Clin Exp Med. 21(4):750–755. doi: 10.15584/ejcem.2023.4.14.
Arinola GO, Onifade AA, Edem VF and Yaqub SA (2021d). Detection of anti SARS-COV 2 specific -IgG and -IgM antibodies in COVID-19 patients using rapid screening immunochromatographic cassettes. Annals of Epidemiology and Public Health. 4(1): 1059.
Arinola O.G (2020). Immune Responses During Human Coronavirus Infection: Suggestions For Future Studies: Nigerian Journal of Physiological Sciences. 35: 20-25.
Arinola O.G and Edem V.F (2020). Antioxidant Vitamins are correlated with Different Aspects of Phagocytic Processes in Healthy Nigerians: Benefit as Supplements during Antimicrobial Treatment. Sudan Journal of Medical Sciences. 15 (3): 223–234. DOI 10.18502/sjms.v15i3.7253.
Arinola O.G, Edem V.F, Rahamon S.K, Yaqub S.A, Fashina A.O and Alonge T.O. (2020). SARS-CoV-2 Infection Screening Using Two Serological Testing Methods. Nigerian. J. Physiol. Sci. 35 (December 2020): 117 – 121.
Arinola OG. (2021). Serum Levels of Anti-Corona Virus Specific-IgG and -IgM Antibodies in COVID-19 Patients At Admission and At Discharge. European Journal of Clinical and Experimental Medicine. 19(1): 5-9.
Arinola OG, Rahamon SK, Edem VF, Yaqub SA, Fashina OA, Alonge TO. (2021g). Elevated plasma level of circulating immune complexes in Nigerian adults infected with Severe Acute Respiratory Syndrome Corona Virus-2. Arch. Basic and Applied Medicine. 9: 69-72
Arinola OG, Rahamon SK, Edem VF, Yaqub SA, Fashina OA, Alonge TO. (2021). Elevated plasma level of circulating immune complexes in Nigerian adults infected with Severe Acute Respiratory Syndrome Corona Virus-2. Arch. Basic and Applied Medicine. 9: 69-72
Arinola, G. O., Edem, F. V., & Alonge, T. O. (2022). Levels of Plasma C-reactive protein, Albumin and Pre-Albumin in Nigerian COVID-19 Patients. Annals of Medical Research, 29(1), 0046–0051. Retrieved from https://annalsmedres.org/index.php/aomr/article/view/4021
Arinola GO, Abdullahi I, Rahamon SK. et al. (2023). Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use. Egypt J Bronchol 17, 2 https://doi.org/10.1186/s43168-022-00174-2
Attah AF, Fagbemi AA, Olubiyi O, Dada-Adegbola H, Oluwadotun A, Elujoba A and Babalola CP. (2021). Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective. Front. Pharmacol. 12:596855. doi: 10.3389/fphar.2021.596855
Du M., et al. (2020). Multi-omics evaluation of gastrointestinal and other clinical characteristics of SARS-CoV-2 and COVID-19. Gastroenterology. 158:2298–2301. doi: 10.1053/j.gastro.2020.03.045. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 117: 9490–9496. doi: 10.1073/pnas.2004168117
Edem VF and Arinola OG (2015). Leucocyte migration and intracellular killing in newly diagnosed pulmonary tuberculosis patients and during anti-tuberculosis chemotherapy. Annals of Global Health. 81(5): 669-674.
Fasasi ZB, Abdullahi I, Kehinde A, Bakare AA & Arinola G. O. (2023). Assessment of Serum Levels of Immunoglobulin A (IgA) Class in Patients with COVID-19 and Asthma. Asian Journal of Immunology. 6(1), 102–111. Retrieved from https://journalaji.com/index.php/AJI/article/view/101.
Fehr AR and Perlman S (2015). Coronaviruses: An Overview of Their Replication and Pathogenesis. Methods Mol Biol. 1282: 1–23. doi: 10.1007/978-1-4939-2438-7_1.
Fintelman-Rodrigues N, Sacramento CQ, Lima CR, Silva DFS, Ferreira AC, Mattos M, et al. (2020). Atazanavir inhibits sars-cov-2 replication and pro-inflammatory cytokine production. bioRxiv [Preprint]. doi: 10.1101/2020.04.04.020925
Fowotade A, Bamidele F, Egbetola B, Fagbamigbe AF, Adeagbo BA, Adefuye BO, Olagunoye A, Ojo TO, Adebiyi AO, Olagunju OI, Ladipo OT, Akinloye A, Onayade A, Bolaji OO, Rannard S, Happi C, Owen A and Olagunju A (2022). A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. Front. Med. 9:956123. doi: 10.3389/fmed.2022.956123
Haase H and L. Rink. (2007). Signal Transduction in Monocytes: The Role of Zinc Ions. Biometals. 20(3): 579–585.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181: 1-10.
Jacofsky D, Jacofsky EM, Jacofsky M. (2020). Understanding Antibody Testing for COVID-19. J Arthroplasty. Jul;35(7S):S74-S81. doi: 10.1016/j.arth.2020.04.055. Epub 2020 Apr 27. PMID: 32389405; PMCID: PMC7184973.
Jiang Y, Zhao T, Zhou X, Xiang Y, Gutierrez-Castrellon P, Ma X. (2020). Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. MedComm (2020). 2022 Aug 1;3(3):e154. doi: 10.1002/mco2.154. PMID: 35923762; PMCID: PMC9340488.
Jose RJ, Manuel A. (2020). COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020; 8: e46-e47.
Kolb P, Giese S, Voll RE, Hengel H, Falcone V. (2023). Immune complexes as culprits of immunopathology in severe COVID-19. Med Microbiol Immunol. Apr;212(2):185-191. doi: 10.1007/s00430-022-00743-8.
Lu J,Wei Z, Jiang H et al. (2018). Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study. J Surg Res. 228:314–321.doi:10.1016/j.jss.2018.03.035.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395:565–74. doi: 10.1016/S0140-6736(20)30251-8
McKechnie JL, Blish CA. (2020). The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? Cell Host Microbe. Jun 10;27(6):863-869. doi: 10.1016/j.chom.2020.05.009. Epub 2020 May 20. PMID: 32464098; PMCID: PMC7237895.
Meo S.A, D.C. Klonoff, J. Akram. (2020). Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. European Review for Medical and Pharmacological Sciences. 24:4539-4547
Olaleye DO, Adewale Victor Opayele, Hyacinth Chukwuebuka Egbuna, Adedayo Omotayo Faneye, Babatunde Adebiyi Olusola, Timothy Segun, Elisabeth Chibuzo Odeh, Magbagbeola David Dairo, Adeniyi Francis Fagbamigbe, Musa Adamu Sarki, Maryam Aminu, Ademola Johnson Ajuwon, Ganiyu Arinola, Chris Ezeora Achi, Sunday Aremu Omilabu, Georgina Njideka Odaibo. (2023) Molecular detection of SARS-CoV-2 infection in three geo-political zones of Nigeria: a cross-sectional study. Pan African Medical Journal. 44:146. [doi: 10.11604/pamj.2023.44.146.37400]
Olaleye DO, Aminu M, Olusola BA, Segun TO, Faneye AO, Opayele AV, Odeh E, Sarki M, Dairo MD, Fagbamigbe AF, Egbuna HC, Ajuwon AJ, Omilabu SA, Achi CE, Odaibo GN and Arinola OG (2022). High Seroprevalence of SARS-COV-2 Antibody before Covid-19 Vaccination in Nigerian Communities. International Archives of Public Health and Community Medicine. DOI:10.23937/2643-4512/1710083. ISSN: 2643-4512.
Olubiyi OO, Olagunju M, Keutmann M, Loschwitz J, Strodel B. (2020). High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. Molecules. 25. 3193. https://doi.org/10.3390/molecules25143193
Onifade AA, Rahamon SK and Arinola OG. (2023a). Serum lactate dehydrogenase activity in COVID-19 patients at admission and discharge from an isolation center: Suggestion as metabolic checkpoint. Arch. Bas. App. Med.11(1):32-36.
Onifade AA and Arinola OG (2020). Albendazole reduces serum levels of inflammatory cytokines: Potential strategy for the management of cytokine storm”. Saudi Journal of Biomedical Research. 5 (11): 320-324. DOI : 10.36348/sjbr.2020.v05i11.006
Onifade AA, Fowotade A, Rahamon SK, Edem VF, Yaqub SA, Akande OK, Arinola OG. (2023b). Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians. PLoS ONE 18(1): e0280276. https://doi. org/10.1371/journal.pone.028027
Peiris JS et al. (2003). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 361(9371):1767–1772
Rahamon SK, Arinola OG, Charles-Davies MA, et al. (2021). Serum levels of vitamin D and tumour necrosis factor-alpha in adults with metabolic syndrome. Eur J Clin Exp Med. 19(4):306–312. doi: 10.15584/ejcem.2021.4.3.
Schneider WM, Chevillotte MD, Rice CM. (2014). Interferon gamma stimulated genes: a complex web of host defenses. Annu Rev Immunol. 32: 513‐ 545.
Sepulveda J. (2013). Challenges in Routine Clinical Chemistry Analysis: Proteins and Enzymes. Editor(s): A. Dasgupta, J. L. Sepulveda, Chapter 9, Accurate Results in the Clinical Laboratory, Elsevier,2013:131-148.
Ünüvar S, Erge D, Kılıçarslan B, Bağ H, Girgin G and Baydar T. (2019). Neopterin Levels and Indoleamine 2,3-Dioxygenase Activity as Biomarkers of Immune System Activation and Childhood Allergic Diseases. Ann Lab Med. 39(3): 284-290. https://doi.org/10.3343/alm.2019.39.3.284.
WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020. World Health Organization. 11 March 2020. Retrieved 11 March 2020.
Wu F., et al. (2020). Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. MedRxiv Preprint , https://doi.org/10.1101/2020.1103.1130.20047365 (2020).
Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong AN. (2020). An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 11:1-15. doi: 10.1007/s40495-020-00216-
Yang L, Shasha Liu, Jinyan Liu, Zhixin Zhang, Xiaochun Wan, Bo Huang, Youhai Chen and Yi Zhang. (2020) COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduction and Targeted Therapy. 5;128:1-8.
Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. (2020). Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv [preprint] 2020.02.11.20021493. doi: 10.1101/2020.02.11.20021493CrossRef Full Text | Google Scholar
Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. (2005). In vitro inhibition of udp glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 33:1729–39. doi: 10.1124/dmd.105.005447
Tato práce je licencována pod Mezinárodní licencí Creative Commons Attribution 4.0 .
Copyright (c) 2025 Nigerian Journal of Physiological Sciences